144: Filer Information

Filer CIK

0001832794

Filer CCC

XXXXXXXX

Is this a LIVE or TEST Filing?

LIVE

TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer

MARAVAI LIFESCIENCES HOLDINGS, INC.

SEC File Number

001-39725

Address of Issuer

10770 Wateridge Circle
Suite 200
San Diego
CALIFORNIA
92121

Phone

858-546-0004

Name of Person for Whose Account the Securities are To Be Sold

Maravai Life Sciences Holdings 2, LLC

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Owner

144: Securities Information

Title of the Class of Securities To Be Sold

Class A common stock, par value $0.01 per share

Name and Address of the Broker

Goldman Sachs & Co. LLC
200 West Street
New York
NY
10282

Number of Shares or Other Units To Be Sold

1531028

Aggregate Market Value

16504481.84

Number of Shares or Other Units Outstanding

132830872

Approximate Date of Sale

05/28/2024

Name the Securities Exchange

Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class

Class A common stock, par value $0.01 per share

Date you Acquired

11/19/2020

Nature of Acquisition Transaction

Pre-IPO reorganization

Name of Person from Whom Acquired

Maravai LifeSciences Holdings, Inc.

Is this a Gift?

Date Donor Acquired

Amount of Securities Acquired

28965664

Date of Payment

11/19/2020

Nature of Payment

Securities of the issuer were received in connection with a series of reorganization transactions prior to the issuer's IPO.

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

(1) Based on the closing price on May 28, 2024 of $10.78. (2) As of May 2, 2024 (as reported on the Issuer's Form 10-Q for the quarter ended March 31, 2024, filed with the Securities and Exchange Commission on May 9, 2024).

Date of Notice

05/28/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Kevin Herde